Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Revolution Medicines (RVMD) Net Income towards Common Stockholders: 2018-2024

Historic Net Income towards Common Stockholders for Revolution Medicines (RVMD) over the last 7 years, with Dec 2024 value amounting to -$600.1 million.

  • Revolution Medicines' Net Income towards Common Stockholders fell 95.28% to -$305.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$961.0 million, marking a year-over-year decrease of 69.47%. This contributed to the annual value of -$600.1 million for FY2024, which is 37.52% down from last year.
  • Latest data reveals that Revolution Medicines reported Net Income towards Common Stockholders of -$600.1 million as of FY2024, which was down 37.52% from -$436.4 million recorded in FY2023.
  • Revolution Medicines' Net Income towards Common Stockholders' 5-year high stood at -$110.4 million during FY2020, with a 5-year trough of -$600.1 million in FY2024.
  • For the 3-year period, Revolution Medicines' Net Income towards Common Stockholders averaged around -$428.4 million, with its median value being -$436.4 million (2023).
  • Data for Revolution Medicines' Net Income towards Common Stockholders shows a maximum YoY slumped of 78.31% (in 2020) over the last 5 years.
  • Over the past 5 years, Revolution Medicines' Net Income towards Common Stockholders (Yearly) stood at -$110.4 million in 2020, then tumbled by 69.50% to -$187.1 million in 2021, then slumped by 32.93% to -$248.7 million in 2022, then slumped by 75.46% to -$436.4 million in 2023, then slumped by 37.52% to -$600.1 million in 2024.